Volume 27, Number 4—April 2021
CME ACTIVITY - Synopsis
Blastomycosis Surveillance in 5 States, United States, 1987–2018
Table 2
Test type | No. (%) |
---|---|
Antibody | 59 (4.8) |
Immunodiffusion | 18 (1.5) |
Complement fixation | 7 (0.6) |
Enzyme immunoassay | 30 (2.4) |
Unspecified antibody test |
17 (1.4) |
Antigen |
206 (16.6) |
Confirmatory test | 965 (77.8) |
Culture | 835 (67.3) |
Microscopy* | 333 (26.8) |
DNA probe | 40 (3.2) |
PCR | 2 (0.2) |
Unspecified test type |
166 (13.4) |
Specimen type | |
Culture | 769 (100) |
Bronchial specimen | 372 (48.4) |
Sputum | 180 (23.4) |
Other tissue besides lung | 121 (15.7) |
Lung tissue | 21 (2.7) |
Multiple specimen types | 14 (1.8) |
Other | 61 (7.9) |
Microscopy | 342 (100) |
Bronchoalveolar lavage | 110 (32.2) |
Sputum | 78 (22.8) |
Other tissue besides lung | 52 (15.2) |
Lung tissue | 47 (13.7) |
Multiple specimen types | 24 (7.0) |
Other | 31 (9.1) |
*Includes smear, histopathology, and unspecified microscopy tests.
Page created: February 09, 2021
Page updated: March 17, 2021
Page reviewed: March 17, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.